Application of Log-Linear Model in Inference on Karyotypic Evolution in Chronic Myelocytic Leukemia

by Tetsuo Hashimoto,* Megu Ohtaki,* Nanao Kamada,* Hisashi Yamamoto,† and Masaki Munaka*

Relationships among additional chromosome abnormalities in chronic myelocytic leukemia (CML) with translocation 9;22 (Philadelphia chromosome (Ph1)-positive CML) were analyzed by log-linear models on 709 karyotypes reported in the literature. Additional abnormalities, such as the gain of chromosome 8 (+8), gain of Philadelphia chromosome (+Ph), isochromosome of the long arm (q) of chromosome 17 (i(17q)), and the gain of chromosome 19 (+19), were frequently observed. A four-way $2 \times 2 \times 2 \times 2$ contingency table was considered with respect to the appearance of these four abnormalities, then the hierarchical log-linear models having at least four main effects were fitted to the observed contingency table. Akaike's information criteria of the models reflected the fitness of the model very well. Parameter estimates of the interaction terms indicated that the combinations of two abnormalities, +8 and +19, +Ph and +19, and +8 and i(17q) were positively associated, while +Ph and i(17q), and +19 and i(17q) were negatively associated. Based on the results of the data analysis, an inference was made on the route of karyotypic evolution in Ph1-positive CML; it statistically supports the hypothesis presented by Heim and Mitelman.

Introduction

The translocation 9;22 found in the karyotypes of chronic myelocytic leukemia (CML) patients is strongly associated with CML as a specific chromosome abnormality. It is regarded as a primary abnormality that plays a fundamental role in initiating the malignant process of CML (1). Additional chromosome abnormalities superimposed on the translocation 9;22, such as +Ph, +del(22)(q11), etc., +8 and/or i(17q) also occur in most patients with CML in blastic crisis. These abnormalities reflect the karyotypic evolution of malignant cells in vivo (2–4).

Heim and Mitelman (4) presented a hypothesis of karyotypic evolution in CML patients by analyzing the patterns of additional chromosome abnormalities other than translocation 9;22. The major route of karyotypic evolution by their hypothesis was as follows: +8, +Ph, or i(17q) are the main additional changes after a translocation 9;22 occurs; +19, on the other hand, seems to occur later in karyotypic evolution, most often in combination with both +8 and +Ph; i(17q) in combination with +8 is a quite frequent phenomenon, whereas the combinations i(17q) and +19, +Ph and i(17q), +8, i(17q), and +19, and +Ph and i(17q), and +19 are only seen very rarely. These findings testify to the fact that i(17q) apparently has a restrictive role in the cytogenetic evolution in CML, at least when no extra chromosome 8 is present in the cells. The hypothesis, however, is derived from single-column frequencies of combinations of abnormalities, such as +Ph and +8 and +Ph and i(17q), without analysis of associations among additional abnormalities.

In the present study, we analyzed 709 cases of Ph1 positive CML karyotypes with additional abnormalities that were derived from the same database of Mitelman et al. (4) and quantified the relationships among additional abnormalities by means of multivariate analysis of frequency table (log-linear models).

Materials and Methods

The material used in this study consisted of 709 Ph1-positive CML karyotypes with additional abnormalities, which were collected from the Catalog of Chromosome Aberrations in Cancer, second edition (5). Single-column frequencies of the additional abnormalities were analyzed by our previously reported computer program (6–8). A four-way $2 \times 2 \times 2 \times 2$ contingency table where the four indices pertain to categorical (none or
present) variables $A$: $+8$, $B$: $+Ph^1$, $C$: $i(17q)$, and $D$: $+19$ was considered, and then log-linear models (9) were fitted to the observed four-way contingency table. The analysis contained 113 hierarchical models with at least four main effects; a saturated model was excluded.

For example, the model only with four main effects, that is, the independent model, is:

$$\log m_{ijkl} = \mu + \lambda_i^A + \lambda_j^B + \lambda_k^C + \lambda_l^D$$

$$[A,B,C,D] \quad \text{(Model 1)}$$

where $m_{ijkl}$ is the expected value of observed cell frequency and $\mu$ and $\lambda$'s values are unknown parameters.

The model with four main effects and six terms of two-way interactions, that is, the second-order full model, is:

$$\log m_{ijkl} = \mu + \lambda_i^A + \lambda_j^B + \lambda_k^C + \lambda_l^D$$

$$+ \lambda_{ij}^{AB} + \lambda_{ik}^{AC} + \lambda_{jk}^{AD} + \lambda_{kl}^{BC}$$

$$+ \lambda_{ij}^{BD} + \lambda_{kl}^{CD}$$

$$[AB,AC,AD,BC,BD,CD] \quad \text{(Model 80)}$$

The model with four main effects, six terms of two-way interactions, and four terms of three-way interactions, that is, the third order full model, is:

$$\log m_{ijkl} = \mu + \lambda_i^A + \lambda_j^B + \lambda_k^C + \lambda_l^D$$

$$+ \lambda_{ij}^{AB} + \lambda_{ik}^{AC} + \lambda_{jk}^{AD} + \lambda_{kl}^{BC}$$

$$+ \lambda_{ij}^{BD} + \lambda_{kl}^{CD}$$

$$+ \lambda_{ijkl}^{ABC} + \lambda_{ijkl}^{ABD} + \lambda_{ijkl}^{ACD} + \lambda_{ijkl}^{BCD}$$

$$[ABC,ABD,ACD,BCD] \quad \text{(Model 113)}$$

To evaluate the goodness of the fit for 113 models, Akaike's information criteria (AIC) (10) was calculated for each model:

$$\text{AIC} = G^2 - 2df$$

where $G^2$, $df$ represents the likelihood ratio chi-square, the degrees of freedom, of the model, respectively.

Generally, two models $M_1$ and $M_2$ are said to be nested if all of the $\lambda$ effects in $M_1$ are a subset of the $\lambda$ values contained in $M_2$. Conditioning the effects in $M_1$, the difference in $G^2$ between the $M_1$ and the $M_2$ is the test of the additional effects in $M_2$. This difference also has an asymptotic chi-square distribution with degrees of freedom equal to the difference in the number of parameters fitted to the two models. Therefore, to test the significance of two- or three-way interactions, the difference in the $G^2$ between one model and the other model which does not contain the attended interaction was computed. The program package BMDP (11) was used for these analyses.

**Results and Discussion**

Additional chromosome abnormalities frequently found in the 709 karyotypes from $Ph^1$-positive CML patients were $+8$ (253 cases, 35.6%), $+Ph^1$ (238 cases, 33.5%), $i(17q)$ (184 cases, 25.9%), $+19$ (109 cases, 15.3%), $+21$ (48 cases, 6.7%), $+17$ (44 cases, 6.2%), $+10$ (29 cases, 4.0%), -7 (28 cases, 3.9%), and -Y (17 cases, 2.3%). All of the other additional abnormalities were less than 2% of 709 cases.

Table 1 shows the $2 \times 2 \times 2 \times 2$ contingency table with respect to the presence of four main abnormalities ($+8$, $+Ph^1$, i($17q$), and $+19$). The table contains the raw data of this analysis.

Table 2 summarizes the degrees of freedom (df), likelihood ratio chi-square ($LR \chi^2$), and the AIC of the 113 hierarchical models at least with four main effects. AICs are graphically plotted on the right-hand side of the table. Of all the 113 AICs, 19 AICs were less than 0. The maximum and minimum values of AIC were 188.49 in Model 1 (the independent model) and -5.68 in Model 108. In the models with one or two terms of two-way interactions (Models 2 through 22), all of the AICs were greater than 50. In the models with three terms of two-way interactions (Models 23 through 42), the model [AD,BC,BD] (Model 39) which has the interactions of $A^* = +8$ and $D = +19$, $B = +Ph^1$ and $C$: i($17q$), and $B$: $+Ph^1$ and $D$: $+19^*$ indicated the lowest AIC value (11.01). In the models with four terms of two-way interactions (Models 43 through 57), [AC,AD,BC,BD] (Model 53) and [AD,BC,BD,CD] (Model 57) (both of which have the terms, $AD$, $BC$, and $BD$ included in Model 39) indicated lower AIC values than other models—that is, 5.65 and 6.36, respectively. These two models have no two-way interaction of $A^* = +8$ and $B$: $+Ph^1$. Comparison of the AICs of both [AD,BC,BD] (Model 39) and [AB,AD,BD,BD] (Model 49) indicates that the two-way interaction of $AB$ does not contribute to increase a fitness. In the models with five terms of two-way interactions (Models 62 through 67), [AC,AD,BC,BD,CD] (Model 67) was the best with an AIC value of $-2.93$. The AIC was especially lower than other models, and it was the tenth lowest value of all the 113 AICs. The AIC of the second-order full model (Model 80) was $-3.69$, which was the fifth lowest value. In the models with five terms of two-way interactions and one or two of three-way interactions (Models 81 through 98), Models 89, 92, and 98 (which lacked the two-way term $AB$) indicated essentially lower AIC values than others, that is, $-1.11$, $-1.46$, and 0.36, re-

---

### Table 1. Observed frequency table with respect to the presence of four main abnormalities (raw data of the analysis).

| Presence of abnormalities | + 8 N* | + 8 P* | Total |
|---------------------------|--------|--------|-------|
| + 19 N                    | i(17q) | Ph^1   | 207   | 65   | 272 |
| + 19 P                    | i(17q) | Ph^1   | 106   | 47   | 153 |
| Total                     |        |        | 313   | 112  | 425 |
| + 19                       | i(17q) | Ph^1   | 102   | 60   | 162 |
| + 19                       | Ph^1   |         | 4     | 9    | 13  |
| Total                     |        |        | 106   | 69   | 175 |
| + 19                       | i(17q) | Ph^1   | 9     | 22   | 31  |
| + 19                       | Ph^1   |         | 27    | 42   | 69  |
| Total                     |        |        | 36    | 64   | 100 |
| + 19                       | i(17q) | Ph^1   | 1     | 5    | 6   |
| + 19                       | Ph^1   |         | 0     | 3    | 3   |
| Total                     |        |        | 1     | 8    | 9   |

* N: none.  
* P: present.
respectively. These three AICs, the AIC of 
\[ \{AC,AD,BC,BD,CD\} \] (Model 67), and several previous results suggest that the appearance of \( A: +8 \) and \( B: +P \) tend to be independent. All the models with six terms of two-way interactions and one or more of three-way interactions (Models 99 through 113) had lower AIC values than 0. In these models, the six terms of two-way interactions and two of three-way interactions \( \{CD,ABC,ABD\} \) (Model 103), indicated a minimum AIC value of all the 113 AICs. The models with six terms of two-way interactions and one of three-way interaction, \( \{AD,BD,CD,ABC\} \) (Model 99) and \( \{AC,BC,CD,ABD\} \) (Model 100), had the second and the third lowest AICs, respectively.

Table 3 shows the expected frequencies by Models 1, 80, and 103. No good fitness was found between observed frequencies \([O]\) and expected frequencies \([E]\) by the independent model only with four main effects (Model 1). For example, the value of \([O]/[E] - 1\), which indicates the deviation of \([O]\) from \([E]\), was +3.15 on the cell, corresponding to the presence of \( +8 \), \( +P \), and \( +19 \) (pattern 7). It means that the expected frequency \([E]\) was underestimated. Conversely, the value of \([O]/[E] - 1\) was \(-0.74\) on the cell of \( +19 \) (pattern 10), meaning that \([E]\) was overestimated. Therefore, the presence of \( +19 \) may not be explained without considering the interactions of more than two factors. However, the fitness of \([O]\) and \([E]\) by the second-order full model (Model 80) was considerably improved, and the values of \([O]/[E] - 1\) closed with 0. The values of \([O]/[E] - 1\) with the best model regarding AIC (Model 103) were nearly 0. The fitness was very good.

(Continued on next page)
Table 2. Continued.

| Model no. | \((A, B, C, D +)\) | \(\text{df} \) | \(\text{LR}^2\) | AIC | Value of AIC^5 |
|-----------|---------------------|--------------|----------------|-----|---------------|
| 58        | AB AC BC ABC        | 7            | 114.21         | 100.21 |               |
| 59        | AB AD BD ABD        | 7            | 101.79         | 87.79  |               |
| 60        | AC AD CD ACD        | 7            | 127.66         | 115.66 |               |
| 61        | BC BD CD BCD        | 7            | 68.96          | 54.96  |               |
| 62        | AB AC AD BD ABC     | 7            | 16.31          | 5.31   |               |
| 63        | AB AC BD CD ABC     | 7            | 28.35          | 25.35  |               |
| 64        | AB AC AD BD ACD     | 7            | 70.35          | 58.35  |               |
| 65        | AB AC BD CD ACD     | 7            | 53.12          | 41.12  |               |
| 66        | AB AC BD CD ACD     | 7            | 19.94          | 7.94   |               |
| 67        | AC AD BD CD ACD     | 7            | 9.07           | 2.93   |               |
| 68        | AB AC BD BC ABD     | 6            | 91.97          | 79.97  |               |
| 69        | AB AC BC BD ABD     | 6            | 57.14          | 45.14  |               |
| 70        | AB AC AD BC ABD     | 6            | 65.08          | 53.08  |               |
| 71        | AD AD BD ABD        | 6            | 34.51          | 12.51  |               |
| 72        | AC AD BD ACD        | 6            | 97.62          | 85.62  |               |
| 73        | AD AD BD ACD        | 6            | 70.39          | 58.39  |               |
| 74        | AC AD BC ACD        | 6            | 50.37          | 38.37  |               |
| 75        | AD AC BC ACD        | 6            | 120.57         | 108.57 |               |
| 76        | AC AD BC ACD        | 6            | 19.82          | 7.82   |               |
| 77        | AC BC BD ACD        | 6            | 64.78          | 52.78  |               |
| 78        | AB AC BD CD ACD     | 5            | 61.35          | 49.35  |               |
| 79        | AB AC BD CD ACD     | 5            | 5.31           | 2.31   |               |
| 80        | AB AC BD CD ACD     | 5            | 15.46          | 5.46   |               |
| 81        | AB AC BD CD ACD     | 5            | 35.73          | 23.73  |               |
| 82        | AB AC BD CD ACD     | 5            | 50.49          | 40.49  |               |
| 83        | AB AC AD BD ABD     | 5            | 15.23          | 5.23   |               |
| 84        | AC AD BD ACD        | 5            | 68.27          | 56.27  |               |
| 85        | AB AD BD ACD        | 5            | 17.96          | 7.96   |               |
| 86        | AB AD BD ACD        | 5            | 38.17          | 26.17  |               |
| 87        | AB AD BD ACD        | 5            | 70.17          | 58.17  |               |
| 88        | AB AD BD ACD        | 5            | 8.91           | 1.91   |               |
| 89        | AB AD BD ACD        | 5            | 52.58          | 40.58  |               |
| 90        | AB AD BD ACD        | 5            | 15.40          | 5.40   |               |
| 91        | AB AD BD ACD        | 5            | 5.31           | 2.31   |               |
| 92        | AC AD AC ACD        | 5            | 8.54           | 1.54   |               |
| 93        | AC AD AC ACD        | 5            | 12.60          | 4.60   |               |
| 94        | AC AD AC ACD        | 5            | 35.55          | 27.55  |               |
| 95        | AC AD AC ACD        | 5            | 49.95          | 31.95  |               |
| 96        | AC AD AC ACD        | 5            | 68.09          | 56.09  |               |
| 97        | AC AD AC ACD        | 5            | 17.32          | 9.32   |               |
| 98        | AC AD AC ACD        | 5            | 8.36           | 0.36   |               |
| 99        | AC AD AC ACD        | 5            | 2.59           | 0.59   |               |
| 100       | AC AD AC ACD        | 5            | 4.46           | 2.46   |               |
| 101       | AC AD AC ACD        | 5            | 6.08           | 1.08   |               |
| 102       | AC AD AC ACD        | 5            | 4.57           | 2.57   |               |
| 103       | AC AD AC ACD        | 5            | 3.02           | 1.02   |               |
| 104       | AC AD AC ACD        | 5            | 2.53           | 1.53   |               |
| 105       | AC AD AC ACD        | 5            | 3.50           | 1.50   |               |
| 106       | AC AD AC ACD        | 5            | 3.45           | 1.45   |               |
| 107       | AC AD AC ACD        | 5            | 2.64           | 1.64   |               |
| 108       | AC AD AC ACD        | 5            | 5.57           | 3.57   |               |
| 109       | AC AD AC ACD        | 5            | 0.31           | 0.03   |               |
| 110       | AC AD AC ACD        | 5            | 2.46           | 1.46   |               |
| 111       | AC AD AC ACD        | 5            | 3.02           | 1.02   |               |
| 112       | AC AD AC ACD        | 5            | 2.63           | 1.63   |               |
| 113       | AC AD AC ACD        | 5            | 1.01           | 0.01   |               |

* In a hierarchical model, a higher effect cannot be present unless all lower order effects whose indices are subsets of the higher order effect are also included in the model; e.g., if \(x_1\) is stated (nonzero), it means that \(x_1, x_2, x_3, x_4, x_5, x_6\) are all present. All effects other than four main ones are described in the left-hand side of the column. Since only hierarchical models are considered in this analysis, models are also described by a minimal set of effects in parentheses.

Parameter estimates of the cells that correspond to 'presence', 'presence and presence', or 'presence and presence' of one, two, or three abnormalities were shown in Table 4 as the values of \(\beta = \exp(\lambda)\). Concerning the six interactions of the given two factors, if the value of parameter \(\beta\) is greater than 1, the two factors are considered to be a positive correlation is suggested between the two factors. Then the parameter estimates and the results of significance tests on Model 80 indicate that '+'8 and i(17q)', '+'8 and +19', and '+'Ph' and +19' were significantly positively associated, while '+'22q' and i(17q)' and '+'19 and i(17q)' were significantly negatively associated. The parameter estimates of the two-way interactions in the second-order full model (Model 80) was not greatly different from those in the third-order full model (Model 113), and then the parameter estimates of the three-way interactions in the third-order full model (Model 113) and the best model (Model 103) were nearly 1. Therefore, the four-way \(2 \times 2 \times 2 \times 2\) contingency table is considered to be fully explained by the second-order full model (Model 80). Furthermore, the second-order model, which only lacks a two-way term \(AB\) (Model 67), is also considered to be a reasonable model.

With regard to the cell of '+'8, +Ph', +19', the observed frequency was quite higher than the expected value by the independent model (Model 1), as shown in pattern 7 in Table 3. The high frequency of the pattern
Table 3. Observed [O] and expected [E] frequencies of four-way $2 \times 2 \times 2 \times 2$ contingency table.

| Pattern number | Abnormalities | Observed frequency (%) | Model $1^{a}$ | Model $80^{b}$ | Model $103^{c}$ |
|----------------|---------------|------------------------|---------------|----------------|-----------------|
| 1              | $+$ + Ph$^1$ + (i(17q)) + 19 | 207(29.1) | 189.4 + 0.09 | 207.9 - 0.00 | 207.5 - 0.00 |
| 2              | $-$ + + $-$ | 106(14.9) | 96.5 + 0.09 | 106.7 - 0.00 | 106.4 - 0.00 |
| 3              | $-$ + + + | 102(14.3) | 95.6 + 0.51 | 94.8 - 0.03 | 102.5 - 0.00 |
| 4              | $+$ + + $-$ | 75(10.1) | 65.8 - 0.33 | 66.1 - 0.01 | 66.2 - 0.01 |
| 5              | $+$ + + + | 64(9.0) | 37.5 - 0.59 | 36.6 - 0.06 | 39.8 - 0.02 |
| 6              | $+$ + + + | 47(6.6) | 46.3 - 0.03 | 46.3 - 0.01 | 46.9 - 0.00 |
| 7              | $+$ + + + | 112(15.9) | 101.1 - 3.15 | 101.3 - 3.05 | 103.5 - 3.05 |
| 8              | $+$ + + + | 27(3.8) | 18.2 - 0.49 | 18.1 - 0.34 | 27.6 - 0.02 |
| 9              | $+$ + + + | 22(3.1) | 19.8 + 0.11 | 19.8 - 0.15 | 21.8 - 0.00 |
| 10             | $+$ + + + | 12(1.7) | 10.2 - 0.74 | 10.2 - 0.28 | 9.5 - 0.05 |
| 11             | $+$ + + + | 9(1.2) | 9.2 - 0.53 | 9.3 - 0.28 | 10.1 - 0.10 |
| 12             | $+$ + + + | 5(0.7) | 7.0 - 0.28 | 6.9 - 0.16 | 6.2 - 0.19 |
| 13             | $+$ + + + | 4(0.6) | 3.4 - 0.80 | 3.4 - 0.50 | 4.4 - 0.13 |
| 14             | $+$ + + + | 3(0.4) | 2.6 - 0.16 | 2.4 - 0.25 | 2.1 - 0.03 |
| 15             | $+$ + + + | 1(0.1) | 1.2 - 0.92 | 1.2 - 0.50 | 1.1 - 0.33 |
| 16             | $+$ + + + | 0(0.0) | 0.6 - 1.00 | 0.6 - 1.01 | 0.3 - 1.00 |

Table 4. Parameter estimates [\(\hat{\beta} = \exp (\hat{\lambda})\)] of log-linear models.

is explained only by the interactions of two factors, such as $'8 + 8$ and $'Ph$' $'i(17q)'$, $'8 + 19'$, and $'Ph$' $'i(17q)'$ and $'19'$. The interaction of three factors such as $'8 + Ph$' $'i(17q)'$, and $'8 + 19'$ would not be necessary.

Figure 1 schematically shows the routine of karyotypic evolution in $Ph$' positive CML inferred by our analysis. That is, after a translocation 9:22 occurs, one of the four abnormalities, $'Ph$' $'8$, $'i(17q)'$, or $'19'$ appears alone or at first then the combination of two abnormalities $'Ph$' $'i(17q)'$, $'Ph$' $'8' + 19'$, and $'i(17q)'$ or $'8 + 19'$ appears in the next step. However, the degree of association differ in their combinations: $'Ph$' $'i(17q)'$, $'8 + 19'$, and $'Ph$' $'i(17q)'$ or $'8 + 19'$ and $'i(17q)'$ appear differently. Furthermore, the third abnormality can be added to the previously formed combination of the two abnormalities (Tables 3 and 1).
Our findings obtained from analyzing the multiway contingency table with respect to the four additional abnormalities statistically support the hypothesis of karyotypic evolution in CML presented by Heim and Mitelman (4). However, our results are derived only from the log-linear analysis. In the next step other methods, such as corresponded analysis or factor analysis, etc., should be applied for the same data set to complement our present analysis. Because the previously mentioned hypothesis results from the analysis based on the karyotypes in a given stage, time-series data analysis of karyotypes from a single patient is also necessary to confirm the hypothesis.

Generally, chromosomal abnormalities of neoplastic cells can be divided into two groups (1). One is a primary abnormality that specifically appears in the initiation of the malignant process. In the case of CML, it is a translocation of 9;22. The other is an additional abnormality that appears during the clonal evolution of neoplastic cells, such as +8, +Ph', and i(17q) in CML. The primary chromosomal changes result in the relocation of cellular oncogenes (12). In the initiation of CML, the cellular oncogene c-abl mapped on the chromosome 9 band q34, which is normally expressed as 6.0–7.0 kb mRNA, and the protein P145^abl is relocated to the bcr gene mapped on the chromosome 22 band q11 (13–15). This event leads to the expression of rearranged genes and their products, that is 8.5 kb mRNA and protein P210^bcr–abl, respectively (16). The abnormal protein with tyrosine kinase activity would probably make cells acquire a proliferative ability. On the other hand, additional chromosome abnormalities relate to the regulation of proliferation and/or differentiation through loss or inactivation of the genes and unbalance of the genome derived from gene amplification. Thus, additional chromosomal changes contribute to the acceleration of the malignancy of the disease. The analysis of the pattern of additional abnormalities, therefore, would give an important clue to the estimation of pathophysiology and prognosis of CML patients.

REFERENCES

1. Mitelman, F. Restricted number of chromosome regions implicated in aetiology of human cancer and leukemia. Nature 310: 325–327 (1984).
2. Mitelman, F., Levan, G., Nilsson, P., and Brandt, L. Non-random karyotypic evolution in chronic myeloid leukemia. Int. J. Cancer. 18: 24–30 (1976).
3. Heim, S., and Mitelman, F. Secondary chromosome aberrations in the acute leukemias. Cancer Genet. Cytogenet. 22: 331–338 (1986).
4. Heim, S., and Mitelman, F. Multistep cytogenetic scenario in
chronic myeloid leukemia. In: Advances in Viral Oncology, Vol. 7 (G. Klein, Ed.), Raven Press, New York, 1987, pp. 53–76.
5. Catalog of Chromosome Aberrations in Cancer, 2nd ed. (F. Mitelman, Ed.), Alan R. Liss, Inc., New York, 1985.
6. Yamamoto, H., Kamada, N., Tanaka, K., Ueoka, H., Ohtaki, M., Munaka, M., Kuramoto, A., and Ohkita, T. Quantitative analysis of the clinical data on leukemia II. Analysis and rearrangement of human karyotype using computer [in Japanese]. J. Hiroshima Med. Assoc. 34: 1066–1073 (1981).
7. Kamada, N., Yamamoto, H., Tanaka, K., Ohtaki, M., Ueoka, H., Munaka, M., and Kuramoto, A. Analysis and rearrangement of human karyotypes by computer. Cancer Genet. Cytogenet. 10: 17–22 (1982).
8. Hashimoto, T., Kamada, N., Yamamoto, H., and Munaka, M. A computer program for analyses of chromosome abnormalities. Acta Haematol. Jpn. 52: 38–48 (1989).
9. Yanagawa, T. Multivariate Analyses for Discrete Data [in Japanese]. Kyooritsu Shuppan Company Ltd., Tokyo, Japan, 1989, pp. 163–178.
10. Tsuruta, S., and Nogami, Y. AICs in log-linear model for contingency tables with poisson and multinomial designs. J. Jpn. Stat. Soc. 16: 165–172 (1986).
11. Dixon, W. J., and Brown, M. B. BMDP Statistical Software, 1983 revised printing, University of California Press, Los Angeles, CA 1983.
12. Land, H., Parada, L. F., and Weinberg, R. A. Cellular oncopgenes and multistep carcinogenesis. Science 222: 771–778 (1983).
13. De Klein, A., Kessel, A. G., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., and Stephenson, R. A cellular oncopgene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300: 765–767 (1982).
14. Bartram, C. R., De Klein, A., Hagemeijer A., Agthoven, T., Kessel, A. G., Bootma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., Heisterkamp, N., Stephenson, J. R., and Groffen, J. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 306: 277–280 (1983).
15. Heisterkamp, N., Stephenson, J. R., Groffen, J., Hansen, P. F., De Klein, A., Bartram, C. R., and Grosveld, G. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature 306: 239–242 (1983).
16. Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A.-M., Witte, O. N., and Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 231: 212–214 (1986).